Lung Cancer

Features of Lung Cancer Treatment–Related AML

By

Andrea S. Blevins Primeau, PhD, MBA

Publish Date December 1, 2020

Therapy-related AML after lung cancer is rare, but is associated with poor prognosis.

New Dosing Option Approved for Imfinzi in NSCLC, Bladder Cancer

By

Brian Park, PharmD

Publish Date November 25, 2020

The approval was based on data from several clinical trials, including the phase 3 PACIFIC trial and the phase 3 CASPIAN trial.

Lorlatinib Superior to Crizotinib for ALK-Positive NSCLC

Publish Date November 25, 2020

Interim analysis shows risk for disease progression or death lower for first-line therapy with lorlatinib versus crizotinib.

Benefit of E-Cigarettes for Quitting Smoking Unclear

Publish Date November 20, 2020

Nicotine e-cigarettes added to counseling improved abstinence at 12 weeks, but not at 24 weeks.

Lung Cancer Tied to Most Potential Years of Life Lost

Publish Date November 20, 2020

Potential years of life lost per death highest for deaths due to cancers of testis, bones/joints, other endocrine sites.

Lung Cancer Clinical Trials

Clinical Trial: Protein and RNA Expression Patterns in Predicting Response to Treatment in Patients With Lung Cancer

Clinical Trial: Improving Management of Breathlessness in Patients With Lung Cancer

Clinical Trial: Lung Cancer Screening Study With Low-dose CT Scan and Blood Biomarker

Clinical Trial: Lung Cancer Biomarkers and Screening (NYULCBC)

Clinical Trial: Proton Therapy for Stage I Non-Small Cell Lung Cancer (LU03)